Regulatory perspective on clinical trials and end points for female sexual dysfunction, in particular, hypoactive sexual desire disorder: formulating recommendations in an environment of evolving clinical science.

Abstract	This article examines the history, current status, and potential future challenges in the development of drugs for female sexual dysfunction (FSD) from the perspective of the United States Food and Drug Administration. In particular, the article focuses on testosterone therapy for hypoactive sexual desire disorder (a component of FSD), and the role of the Division of Reproductive and Urologic Products in facilitating the development of safe and effective therapies for this indication.
Authors	D Shames, S E Monroe, D Davis, L Soule
Journal	International journal of impotence research (Int J Impot Res) 2007 Jan-Feb Vol. 19 Issue 1 Pg. 30-6 ISSN: 0955-9930 [Print] England
PMID	16728969 (Publication Type: Journal Article, Review)
Chemical References	Testosterone
Topics	Clinical Trials as Topic Drug Industry Female Humans Legislation, Drug Sexual Dysfunctions, Psychological (drug therapy) Testosterone (adverse effects, therapeutic use) United States United States Food and Drug Administration

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!